IB Net Payout Yields Model

Hims & Hers Q2 Earnings: Portfolio Cure

Updated Aug. 23, 2023

Hims continues trending down. The stock remains appealing on these dips with software like margins and growth rates. 

Finviz Chart

Update Aug. 17, 2023

Hims & Hers continues to dip following another great earnings report. The online health and wellness platform continues to shift towards profitable precisions treatments, but the market has missed the shift. Definitely a stock to watch for when Hims hits the lows. 

Finviz Chart

Original article published on Aug. 16 

  • Hims & Hers Health, Inc. falls despite a strong Q2 '23 earnings report.
  • The company remains on the path to a 2025 revenue target of $1.2+ billion.
  • The stock is cheap at 1.3x forward EV/S targets for a high gross margin business.
  • Out Fox The Street members get exclusive access to our real-world portfolios. See all of our investments here » 
Despite another strong quarter, Hims & Hers Health, Inc. (NYSE:HIMS) stock fell after Q2 '23 results beat consensus estimates. The stock had already traded weak into the quarterly report due primarily to a short report. My investment thesis is ultra Bullish on HIMS stock following the company showing it is staying on the path to strong growth and profits in the years ahead.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Occidental: Still Producing Too Much Oil

Celsius: Unaltered Growth Story